Anatomy & Physiology Study Guide
3

Cell Structure and Genetic Control of Cell Function

Slide deck, chapter 333 slidesChapter outline and sourcesPractice questions

  1. 3.1

    Fluid mosaic model, leaflet asymmetry and cholesterol

    • The membrane is a lipid bilayer about 5 to 10 nm thick; polar heads face water on both sides and fatty acid tails are buried in the middle.
    • Of the lipids, about 75% are phospholipids, 20% cholesterol and 5% glycolipids; protein is the largest component of the whole membrane (55% in Guyton).
    • Lipids and many proteins slide sideways in their own leaflet; the two leaflets differ, and flippases spend ATP to keep that difference.
    • Phosphatidylcholine and sphingomyelin favor the outer leaflet; phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol face the cytosol; glycolipids sit only outside.
    • Cholesterol wedges between tails: it stiffens a membrane that would be too fluid at body temperature and stops tails packing tightly when cold, buffering fluidity.

    Outcome

    1. 1Describe the fluid mosaic model, including lipid composition, leaflet asymmetry and the role of cholesterol in membrane fluidity.
  2. 3.1

    Integral, peripheral and lipid-anchored proteins

    • Integral proteins cross the bilayer, usually as alpha helices; channels, carriers, pumps and receptors such as G protein-coupled receptors are of this type.
    • Peripheral proteins sit on one surface and bind by electrostatic or protein-protein contacts, so salt can strip them; spectrin and ankyrin under the red cell membrane are examples.
    • Lipid-anchored proteins are tethered by a covalently attached lipid (GPI, prenyl or acyl group) and sit in one leaflet without crossing it.
    • Function classes are transport, receptor, enzyme, cell adhesion, cytoskeletal anchoring and recognition marker; one protein often serves more than one.

    Outcome

    1. 2Distinguish integral, peripheral and lipid-anchored membrane proteins and give one function class for each.
  3. 3.1

    What crosses a bilayer unaided

    • Small nonpolar molecules (O2, CO2, N2) dissolve in the hydrophobic core and cross freely, driven only by their concentration difference.
    • Lipid-soluble molecules such as steroid hormones, ethanol and many drugs cross readily; small uncharged polar molecules, water and urea, cross slowly.
    • Ions and large polar molecules such as glucose are excluded by the hydrophobic core and need a channel, carrier or pump.
    • To predict: rank first by charge and polarity, then by size; a small ion crosses worse than a larger nonpolar molecule.
    • Gradients, carriers and membrane potential are developed in chapter 4.

    Outcome

    1. 3Predict which substances cross a phospholipid bilayer unaided based on size, polarity and charge.
  4. 3.1

    Glycocalyx and phosphatidylserine as signals

    • The glycocalyx is the coat of carbohydrate chains on outer-surface glycoproteins and glycolipids; it mediates adhesion and cell-to-cell recognition.
    • Carbohydrate patterns differ between cell types, so they act as identity tags; ABO blood group antigens are an example.
    • Phosphatidylserine is kept on the cytosolic leaflet by flippases; its appearance on the outer surface is an eat-me signal to phagocytes in apoptosis.
    • On activated platelets the same exposed lipid supports assembly of clotting factors, so one lipid carries different meanings in different cells.

    Outcome

    1. 4Explain how glycocalyx carbohydrates and phosphatidylserine asymmetry serve cell recognition and signaling.
  5. 3.1

    Membrane protein defects that cause disease

    • Hereditary spherocytosis: defective ankyrin or spectrin weakens the link between bilayer and cytoskeleton, the red cell loses membrane and becomes a sphere that the spleen removes.
    • Duchenne muscular dystrophy: absent dystrophin breaks the link between actin and the membrane glycoprotein complex, so contraction damages the sarcolemma.
    • Cystic fibrosis: CFTR is an ATP-gated Cl- channel; the common delta F508 change misfolds it, so it is degraded and never reaches the surface, giving thick secretions.
    • Common thread: the phenotype follows where the protein works, whether a red cell, a muscle fiber or an epithelium.

    Outcome

    1. 5Relate defects in membrane-associated proteins to hereditary spherocytosis, cystic fibrosis and Duchenne muscular dystrophy.
  6. 3.2

    Cytosol compared with extracellular fluid

    • Cytosol is the fluid outside organelles and inside the plasma membrane; it is mostly water with enzymes, glycolysis machinery, free ribosomes and inclusions.
    • K+ is about 140 mEq/L inside against about 4 outside; Na+ is about 10 to 14 mEq/L inside against about 142 outside, maintained by the Na+/K+ pump.
    • Free Ca2+ is held near 100 nM (10^-7 M) against 1 to 2 mM outside, a gradient of 10,000-fold or more, so a small influx is a large signal.
    • Cytosolic pH is about 7.2 (older textbooks say about 7), a little below plasma at 7.4, because metabolism produces acid.
    • Inclusions include glycogen, lipid droplets, lipofuscin, melanin and hemosiderin; the proteasome and autophagy clear damaged proteins and organelles.

    Outcome

    1. 6Describe the composition and ionic makeup of cytosol and its distinction from extracellular fluid.
  7. 3.2

    Endoplasmic reticulum and Golgi apparatus

    • Rough ER is studded with ribosomes and continuous with the nuclear envelope; it folds and glycosylates secretory, membrane and lysosomal proteins, and gives basophilic cytoplasm.
    • Smooth ER lacks ribosomes; it makes phospholipids and steroids, detoxifies drugs with cytochrome P450, releases glucose from hepatic glucose-6-phosphatase and stores Ca2+.
    • The Golgi is a stack of flattened cisternae: the cis face receives from the ER and the trans face ships out; it modifies, sorts and packages cargo.
    • Disease link: the Golgi adds mannose-6-phosphate to lysosomal enzymes, and its failure in I-cell disease sends those enzymes out of the cell.

    Outcome

    1. 7Identify each membranous organelle by structure and function and link it to one disease of dysfunction.
  8. 3.2

    Lysosomes, peroxisomes and mitochondria

    • Lysosomes hold acid hydrolases working at an interior pH of about 4.5 to 5, kept by H+ pumps; their enzyme defects cause storage diseases such as Tay-Sachs, Gaucher and Pompe.
    • Peroxisomes oxidize very-long-chain fatty acids, make plasmalogens and detoxify H2O2 with catalase; defects cause Zellweger syndrome and X-linked adrenoleukodystrophy.
    • Mitochondria have a double membrane; cristae of the inner membrane carry the electron transport chain and ATP synthase, and the matrix runs the Krebs cycle.
    • mtDNA is circular, about 16,500 base pairs with 37 genes (13 proteins, 22 tRNAs, 2 rRNAs), inherited only from the mother; MELAS and LHON are mtDNA diseases.
    • Mitochondria also release cytochrome c in apoptosis, buffer Ca2+ and make heat through UCP1 in brown fat.

    Outcome

    1. 7Identify each membranous organelle by structure and function and link it to one disease of dysfunction.
  9. 3.2

    The secretory pathway and its vesicles

    • Translation starts on a free ribosome; an N-terminal signal peptide is bound by the signal recognition particle, which pauses translation and docks the ribosome at the ER translocon.
    • In the ER lumen the signal is cleaved, N-glycans are added, disulfide bonds form and chaperones such as BiP help folding; misfolded protein triggers the unfolded protein response.
    • COPII-coated vesicles carry cargo from ER to Golgi; COPI vesicles return escaped proteins; cargo matures from cis to trans.
    • At the trans-Golgi network clathrin-coated vesicles sort cargo: constitutive vesicles fuse continuously, secretory granules wait for a Ca2+ signal, and some go to lysosomes.
    • Exocytosis fuses the vesicle with the plasma membrane, releasing contents and adding new membrane and membrane proteins.

    Outcome

    1. 8Trace the secretory pathway from ribosome to plasma membrane and name the transport vesicle types.
  10. 3.2

    Signal sequences as address labels

    • A protein's destination is written in a short sequence within it, which the cell reads as the protein is made or after it is released.
    • An N-terminal signal peptide sends the ribosome to the ER; soluble ER residents carry a C-terminal KDEL signal so that escapees are retrieved from the Golgi.
    • A nuclear localization signal is bound by importin and carried through the nuclear pore; Ran-GTP sets the direction.
    • A mitochondrial presequence is threaded unfolded through TOM and TIM complexes and cleaved in the matrix; peroxisomal proteins carry PTS1.
    • Lysosomal enzymes get a mannose-6-phosphate tag in the Golgi, read by a receptor; with no tag the default is secretion, which is the defect in I-cell disease.

    Outcome

    1. 9Explain how signal sequences direct proteins to the ER, nucleus, mitochondria, lysosomes and the secretory pathway.
  11. 3.2

    Microfilaments, intermediate filaments and microtubules

    • Microfilaments are actin polymers about 7 nm wide (6 to 8 in some references), the thinnest; they form the cortex and microvillus core, drive cytokinesis and motility, and work with myosin.
    • Intermediate filaments are rope-like and 8 to 10 nm wide, built from tissue-specific proteins (keratin, vimentin, desmin, GFAP, neurofilaments, lamins) for mechanical strength.
    • Microtubules are hollow cylinders about 25 nm wide (20 to 25 in some references), built from alpha and beta tubulin dimers, with a plus and a minus end; they radiate from the centrosome.
    • Rank by diameter: microfilament, then intermediate filament, then microtubule; only intermediate filaments are nonpolar, and a keratin defect causes epidermolysis bullosa simplex.

    Outcome

    1. 10Compare microfilaments, intermediate filaments and microtubules by subunit, diameter and function.
  12. 3.2

    Kinesin, dynein and microtubule disease

    • Microtubule minus ends are anchored at the centrosome and plus ends point to the periphery, so the polarity sets the direction of transport.
    • Kinesin walks toward the plus end (anterograde in an axon); dynein walks toward the minus end (retrograde); both use ATP and carry vesicles and organelles.
    • Very long axons depend on this transport, so defects in motors or tubulin are expected to injure neurons first.
    • Colchicine and vincristine block microtubule assembly and paclitaxel freezes microtubules; either way the spindle cannot work and mitosis stalls.

    Outcome

    1. 11Explain how kinesin and dynein move cargo and how microtubule defects cause disease.
  13. 3.2

    Centrioles, cilia and primary ciliary dyskinesia

    • A centriole is a cylinder of nine microtubule triplets; a pair at right angles forms the centrosome, whose surrounding material nucleates spindle and cell microtubules.
    • A cilium has a core of 20 microtubules: nine outer doublets around one central pair; the axoneme grows from a basal body that is structured like a centriole.
    • Dynein arms between doublets slide them to bend the cilium, and the oar-like beat moves mucus along the respiratory epithelium.
    • In primary ciliary dyskinesia the dynein arms are defective: recurrent sinusitis, bronchiectasis and infertility follow, and in Kartagener syndrome situs inversus.

    Outcome

    1. 12Describe the structure of cilia and centrioles and the effects of primary ciliary dyskinesia.
  14. 3.3

    Nuclear envelope, pores, lamina and transport

    • The envelope is two lipid bilayers; the outer one is continuous with rough ER, so the perinuclear space is continuous with the ER lumen.
    • Each nuclear pore complex weighs about 125 MDa (about 50 nucleoporins); passive diffusion fades near 40 kDa, and small molecules cross channels with an effective width near 9 nm.
    • Larger cargo needs a signal: a nuclear localization signal binds importin, and GTP-driven transport through the pore, directed by Ran, carries it in; exportins reverse this.
    • The lamina (lamins A, B, C) lines the inner membrane; phosphorylation of lamins dissolves the envelope in prophase, and LMNA mutations cause laminopathies including Hutchinson-Gilford progeria.
    • The nucleolus is a nonmembranous site of rRNA transcription and ribosomal subunit assembly, prominent in cells making much protein.

    Outcome

    1. 13Describe the nuclear envelope, nuclear pores and nuclear lamina and how nucleocytoplasmic transport works.
  15. 3.3

    Nucleosomes to chromosomes; eu- and heterochromatin

    • A nucleosome is DNA wrapped twice around a core of eight histones (two each of H2A, H2B, H3 and H4); H1 binds the linker DNA between beads.
    • Beads-on-a-string coils into a thicker fiber, then folds into loops; before division the loops condense further to give mitotic chromosomes.
    • The genome of nearly 3.2 billion nucleotides is carried on 46 chromosomes in a somatic cell; stretched out, the DNA of one nucleus is about 2 m long.
    • Euchromatin is open, pale and transcribed; heterochromatin is condensed, dark and silent; a Barr body is the inactivated X.
    • On a slide a large pale nucleus with a prominent nucleolus means an active cell; a small dark one means a quiescent cell.

    Outcome

    1. 14Explain how DNA is packaged into nucleosomes, chromatin and chromosomes and relate eu- and heterochromatin to transcriptional activity.
  16. 3.3

    Methylation, histone marks and X-inactivation

    • Histone acetyltransferases acetylate histones, loosening DNA and opening chromatin; histone deacetylases reverse this and compact it.
    • Methylation of cytosine in CpG islands at a promoter recruits proteins that compact chromatin and silence the gene.
    • These marks are copied at replication, so they pass to daughter cells; this keeps cell identity and underlies imprinting.
    • In early development one X in each female cell is silenced at random and stays silent in all descendants, so a female is a mosaic and the inactive X forms a Barr body.
    • In cancer, promoter methylation can silence tumor suppressor genes, which is why inhibitors of histone deacetylase are used as drugs.

    Outcome

    1. 15Explain how DNA methylation and histone modification regulate gene expression and X-inactivation.
  17. 3.3

    Semiconservative replication and its enzymes

    • Semiconservative: each daughter duplex keeps one old strand and gains one new strand; replication starts at many origins and runs both ways during S phase.
    • Helicase unwinds the helix, single-strand binding protein holds the strands apart, and topoisomerase relieves supercoiling ahead of the fork (target of etoposide and irinotecan).
    • Primase lays a short RNA primer; DNA polymerase can only add to a 3' end, so every new strand is built 5' to 3'.
    • The leading strand is made continuously; the lagging strand is made as Okazaki fragments of about 150 to 200 nucleotides (about 1,200 in bacteria), then primers go and ligase seals the gaps.
    • Proofreading by a 3' to 5' exonuclease and then mismatch repair fix errors: polymerases slip about once per 10^4 to 10^5 nucleotides, yet the net rate is about 10^-10 per base pair per division.

    Outcome

    1. 16Describe the steps and enzymes of semiconservative DNA replication, including leading and lagging strand synthesis.
  18. 3.3

    DNA repair pathways and their syndromes

    • Base excision repair removes single oxidized or deaminated bases; nucleotide excision repair removes bulky lesions such as UV thymine dimers and is defective in xeroderma pigmentosum.
    • Mismatch repair (MSH2, MLH1) fixes errors left after replication; its loss causes Lynch syndrome, hereditary colorectal cancer with microsatellite instability.
    • Double-strand breaks are repaired by homologous recombination (BRCA1, BRCA2), which is accurate, or by error-prone nonhomologous end joining; BRCA loss raises breast and ovarian cancer risk.
    • Damage is sensed by ATM and ATR kinases, which act through p53 to arrest the cycle or trigger apoptosis.

    Outcome

    1. 17Compare the DNA repair pathways and relate each to a hereditary cancer or disease syndrome.
  19. 3.3

    Telomeres, telomerase, aging and cancer

    • Telomeres are repeats (TTAGGG) at chromosome tips that protect the ends from erosion and from sticking together.
    • A lagging strand cannot be primed at the very end of a linear chromosome, so in most somatic cells every division shortens telomeres.
    • Critically short telomeres trigger p53-dependent arrest or death; this is the Hayflick limit on somatic divisions and contributes to aging.
    • Telomerase carries its own RNA template and a reverse transcriptase to rebuild the repeats; it is active in germ and stem cells, but low in most somatic cells.
    • Most cancers switch telomerase back on, which lets them divide without limit.

    Outcome

    1. 18Explain how telomeres and telomerase relate to cell aging and cancer.
  20. 3.4

    Transcription by RNA polymerase II

    • RNA is made 5' to 3' by reading the template strand 3' to 5'; Pol II makes mRNA, Pol I makes rRNA and Pol III makes tRNA.
    • Promoter: TBP of TFIID binds the TATA box (TATAAA) about 25 to 35 bases upstream of the start, and a CAAT box lies near 80 upstream; they recruit Pol II, and enhancers act through Mediator.
    • Initiation opens the helix and joins the first bases; promoter escape frees Pol II to move along the template in elongation, copying with U for T.
    • Termination follows the polyadenylation signal: the transcript is cut and the polymerase is released.
    • Alpha-amanitin from the death-cap mushroom blocks Pol II, so hepatocytes cannot make new mRNA.

    Outcome

    1. 19Describe the steps of transcription by RNA polymerase II, including promoter recognition, initiation, elongation and termination.
  21. 3.4

    mRNA processing

    • A 7-methylguanosine cap is added at the 5' end; it protects the message from exonucleases and helps the ribosome find it.
    • The spliceosome, built from snRNPs, removes introns (which begin GU and end AG) and joins exons; anti-Smith autoantibodies in lupus target snRNPs.
    • A poly-A tail of about 200 A residues is added after cleavage at the polyadenylation signal AAUAAA; it stabilizes the mRNA and aids export and translation.
    • Alternative splicing joins exons in different combinations, and up to about 95% of human multi-exon genes use it, so one gene gives several proteins and proteins outnumber genes.
    • Splice-site mutations can disrupt processing; many cases of beta-thalassemia are of this type.

    Outcome

    1. 20Explain 5' capping, splicing, polyadenylation and alternative splicing in mRNA processing.
  22. 3.4

    Genetic code and classes of point mutation

    • Codons are triplets; AUG codes for methionine and starts translation, and the three stop codons (UAA, UAG, UGA) code for no amino acid.
    • The code is degenerate (several codons per amino acid, with wobble at the third base) and nonoverlapping.
    • Silent: the amino acid is unchanged. Missense: a different amino acid, as GAG to GUG puts Val for Glu in sickle hemoglobin. Nonsense: a premature stop.
    • Frameshift: an insertion or deletion that is not a multiple of three shifts the reading frame, usually scrambling everything downstream; a change of three bases keeps frame.
    • Splice-site and trinucleotide repeat mutations (CAG in Huntington disease, CGG in fragile X) are other classes.

    Outcome

    1. 21Use the genetic code to translate an mRNA and classify point mutations as silent, missense, nonsense or frameshift.
  23. 3.4

    Translation: tRNA, ribosome sites and the three phases

    • Aminoacyl-tRNA synthetases attach the right amino acid to each tRNA; the anticodon then pairs with the mRNA codon, so this charging step sets accuracy.
    • The small ribosomal subunit reads the codon; the large subunit forms peptide bonds, using catalytic RNA rather than a protein enzyme.
    • Initiation: the small subunit binds the cap and scans to the first AUG, the initiator tRNA sits in the P site, and the large subunit joins, using initiation factors and GTP.
    • Elongation: aminoacyl-tRNA enters the A site, the chain is transferred to it, and translocation shifts tRNAs from A to P to E, where the empty tRNA leaves.
    • Termination: a stop codon in the A site recruits a release factor, which frees the chain; many ribosomes on one mRNA form a polysome.

    Outcome

    1. 22Describe the roles of mRNA, tRNA and the ribosome A, P and E sites in initiation, elongation and termination of translation.
  24. 3.4

    Regulating gene expression

    • Transcription factors bind promoters and enhancers; activators recruit the Pol II machinery and repressors block it, so cell-specific combinations give different outputs from identical DNA.
    • Cortisol, thyroid hormone and estrogen cross the membrane, bind intracellular receptors, and the complex binds hormone response elements to change transcription.
    • miRNA and siRNA pair with mRNA through the RISC complex, blocking translation or triggering degradation.
    • Chromatin state and DNA methylation control access to the gene, and ubiquitin-proteasome degradation sets protein half-life.

    Outcome

    1. 23Explain how transcription factors, steroid receptors and non-coding RNAs regulate gene expression.
  25. 3.4

    Drugs and toxins that block gene expression

    • Alpha-amanitin blocks RNA polymerase II, so the block is at transcription of mRNA.
    • Aminoglycosides, tetracyclines and macrolides bind the bacterial ribosome, not the human one: they cause misreading, block tRNA entry at the A site, and block translocation respectively.
    • Diphtheria toxin ADP-ribosylates eEF2, so human translocation stops and protein synthesis halts.
    • Cycloheximide inhibits the eukaryotic ribosome and so is a research tool, not an antibiotic.

    Outcome

    1. 24Relate antibiotics, diphtheria toxin and alpha-amanitin to the specific step of gene expression they block.
  26. 3.5

    Phases of the cell cycle and their durations

    • Interphase is G1, S and G2; the M phase is mitosis plus cytokinesis; G0 is a resting state, permanent in most neurons.
    • G1 varies most, from a couple of hours to many days; S phase typically lasts 8 to 10 h and G2 about 5 h. M phase takes 1 to 2 h, of which mitosis proper is about 30 minutes.
    • G1: growth, organelle duplication and start of centrosome replication. S: DNA doubles, so 46 chromosomes become 92 chromatids. G2: preparation and finished centrosome duplication.
    • Once a cell enters S phase it is committed to finish the cycle.

    Outcome

    1. 25Sequence the phases of the cell cycle and describe what happens in each, with typical durations.
  27. 3.5

    Cyclin-CDK, Rb, p53 and the spindle checkpoint

    • Cyclin levels rise and fall; a CDK is active only when bound to its cyclin, so each transition has its own pair.
    • G1/S: cyclin D-CDK4/6 phosphorylates Rb, which releases E2F to switch on S-phase genes; cyclin E-CDK2 commits the cell. G2/M: cyclin B-CDK1 starts mitosis.
    • DNA damage activates ATM, which stabilizes p53; p53 induces p21, which inhibits CDKs, and arrest allows repair or apoptosis. Without p53 a damaged cell keeps cycling.
    • The spindle assembly checkpoint holds APC/C inactive until every kinetochore is attached, then separase cleaves cohesin so anaphase can begin.

    Outcome

    1. 26Explain how cyclin-CDK complexes, Rb, p53 and the spindle assembly checkpoint control progression of the cell cycle.
  28. 3.5

    Stages of mitosis and cytokinesis

    • Prophase: chromatin condenses into chromosomes of two sister chromatids joined at the centromere; centrosomes move apart and the nucleolus disappears.
    • Prometaphase: the envelope breaks down and spindle microtubules attach to kinetochores. Metaphase: chromosomes line up on the metaphase plate.
    • Anaphase: the sister chromatids separate and are pulled to opposite poles as kinetochore microtubules shorten.
    • Telophase: nuclei reform, chromosomes decondense and nucleoli reappear; an actin-myosin ring makes the cleavage furrow in cytokinesis.
    • The result is two genetically identical diploid daughter cells.

    Outcome

    1. 27Identify the stages of mitosis and cytokinesis and the chromosome state in each.
  29. 3.5

    Meiosis compared with mitosis

    • Meiosis I is reductional: homologs pair in prophase I as tetrads, cross over between nonsister chromatids, then segregate; each cell is haploid but its chromosomes keep two chromatids.
    • Meiosis II is like mitosis: sister chromatids separate, leaving four haploid cells with unreplicated chromosomes.
    • Variation comes from crossing over and from independent assortment: each of the 23 homologous pairs orients at random, giving over eight million (2^23) combinations before crossover.
    • Mitosis is one division giving two identical diploid cells; meiosis is two divisions giving four haploid, genetically different cells.
    • Oocytes arrest in prophase I from fetal life and again in metaphase II until fertilization; spermatogenesis is continuous from puberty.

    Outcome

    1. 28Compare meiosis I and II with mitosis, including crossing over, independent assortment and the ploidy at each stage.
  30. 3.5

    Nondisjunction and aneuploidy

    • Nondisjunction is failure of homologs (meiosis I) or sister chromatids (meiosis II) to separate, giving gametes with an extra or a missing chromosome.
    • After fertilization the zygote has three copies (trisomy) or one copy (monosomy) of that chromosome.
    • Trisomy 21 is Down syndrome; risk rises with maternal age, linked to the long arrest of oocytes in prophase I.
    • Klinefelter syndrome is a male with an extra X; Turner syndrome is a female with a single X, the one monosomy that is often compatible with life.

    Outcome

    1. 29Relate nondisjunction to trisomy 21, Klinefelter and Turner syndromes.
  31. 3.5

    Apoptosis versus necrosis: trigger, form and consequence

    • Apoptosis is regulated and energy-dependent, triggered by development, DNA damage, growth-factor loss, death receptors or cytotoxic T cells; necrosis follows injury such as ischemia.
    • Apoptotic cells shrink, condense chromatin, bleb and break into apoptotic bodies; necrotic cells swell, rupture and leak enzymes.
    • Apoptotic bodies expose phosphatidylserine and are phagocytosed without inflammation; necrosis releases contents and provokes inflammation.
    • Necrosis patterns include coagulative (infarct), liquefactive (brain, abscess), caseous (tuberculosis), fat and fibrinoid.

    Outcome

    1. 30Compare apoptosis with necrosis by trigger, morphology, mechanism and inflammatory consequence.
  32. 3.5

    Intrinsic and extrinsic apoptotic pathways

    • Intrinsic: DNA damage or growth-factor loss lets BAX and BAK form pores, cytochrome c leaves the mitochondria, and with Apaf-1 it forms the apoptosome that activates caspase-9.
    • Bcl-2 and Bcl-xL oppose BAX and BAK and so protect against this pathway.
    • Extrinsic: Fas ligand or TNF binds a death receptor, FADD is recruited and caspase-8 is activated; cytotoxic T cells use perforin and granzyme B.
    • Both pathways converge on the executioner caspases 3 and 7, which cleave cell proteins in a cascade.

    Outcome

    1. 30Compare apoptosis with necrosis by trigger, morphology, mechanism and inflammatory consequence.
  33. 3.5

    How cancer arises: oncogenes, suppressors, survival

    • A proto-oncogene such as RAS or MYC becomes an oncogene through gain of function; this is a stuck accelerator.
    • A tumor suppressor (p53, Rb, BRCA) acts as a brake; its loss lets damaged or crowded cells keep dividing.
    • Failed apoptosis lets mutant cells survive: the t(14;18) translocation puts BCL2 under the immunoglobulin heavy chain enhancers, so BCL2 is overexpressed in follicular lymphoma.
    • The Philadelphia chromosome, a t(9;22) translocation, fuses BCR on chromosome 22 to ABL1 from chromosome 9; BCR-ABL1 is a constantly active kinase in chronic myeloid leukemia, treated with imatinib.
    • Usually several activated oncogenes act together, so cancer is a multi-hit process.

    Outcome

    1. 31Describe how oncogene activation, tumor suppressor loss and failed apoptosis contribute to cancer.